Soy Based Infant Formula Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Form (Powder, Liquid, Semi-Liquid), By Type (Low Fat Soy-based Infant Formula, Whole-Fat Soy-based Infant Formula), By Distribution Channel (Online, Offline), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 308.32 Million
CAGR (2026-2031)	4.67%
Fastest Growing Segment	Online
Largest Market	Asia Pacific
Market Size (2031)	USD 405.54 Million

Market Overview

The Global Soy Based Infant Formula Market will grow from USD 308.32 Million in 2025 to USD 405.54 Million by 2031 at a 4.67% CAGR. Soy-based infant formula is a specialized nutritional substitute derived from soy protein isolate, fortified with essential nutrients to serve as a complete feeding option for infants with galactosemia, hereditary lactase deficiency, or cow’s milk protein allergy. The market is primarily supported by the increasing diagnosis of dairy allergies and a growing parental inclination toward ethical or plant-based dietary lifestyles. According to the Plant Based Foods Association, in 2024, the United States plant-based foods sector reached sales of $8.1 billion, reflecting a resilient consumer shift toward dairy-free alternatives that underpins the demand for soy formulations.

Despite these strong drivers, the market faces a significant challenge regarding the potential biological impact of phytoestrogens naturally present in soy protein. Medical authorities and regulatory bodies frequently express caution regarding the use of soy formula for infants under six months due to concerns over endocrine disruption and hormonal development. This scrutiny limits the product to a secondary recommendation behind hydrolyzed cow's milk formulas, thereby restricting its adoption from a mainstream feeding solution to a niche medical or lifestyle choice.

Key Market Drivers

The Rising Incidence of Cow's Milk Protein Allergy and Lactose Intolerance acts as the primary clinical determinant for the sustained adoption of soy-based infant formulations. As the standard alternative for infants unable to metabolize dairy proteins or lactose, soy formula provides a critical nutritional safety net, particularly for non-IgE mediated allergies where symptoms manifest in the gastrointestinal tract. This medical necessity is reinforced by the robust performance of category leaders who prioritize specialized therapeutic solutions. According to Food Navigator, February 2025, in the 'Danone's 2024 full year results strong' article, the company's specialized nutrition division saw sales increase by 4.6%, highlighting the continued consumer reliance on formulations designed for the dietary management of such sensitivities.

Increasing Parental Preference for Plant-Based and Vegan Infant Nutrition is simultaneously expanding the market beyond strict medical requirements into the lifestyle segment. Modern parents are increasingly seeking clean-label, sustainable, and animal-free nutritional products, compelling manufacturers to optimize supply chains and improve the commercial viability of non-dairy alternatives. This shift toward ethical consumption is fostering improved operational efficiency within the sector. According to Else Nutrition, November 2025, in the 'Q3 2025 Financial Results', the company reported that its gross profit margin surged to 34%, reflecting the growing financial maturity and stability of the plant-based infant nutrition category. Furthermore, the broader industry continues to operate at a massive scale to meet these diverse needs; according to Abbott, in 2025, the company achieved full-year 2024 sales of $42.0 billion, demonstrating the substantial market capitalization supporting global pediatric nutrition innovation.

Download Free Sample Report

Key Market Challenges

The potential biological impact of phytoestrogens in soy protein creates a substantial barrier to the expansion of the global soy-based infant formula market. Because these compounds naturally mimic estrogen, medical professionals and regulatory bodies rigorously limit the product’s application, fearing adverse effects on infant endocrine systems and long-term hormonal development. This medical scrutiny effectively prevents soy formula from being positioned as a mainstream "plant-based" lifestyle choice for the general infant population, relegating it instead to a treatment of last resort.

Consequently, the product is often excluded from the primary standard of care for infants under six months, significantly narrowing its addressable consumer base. The market is further constrained because soy is typically reserved only for specific medical conditions rather than general usage. According to the British Dietetic Association, in 2024, the estimated prevalence of cow's milk protein allergy in young children was reported to be only 2%, yet even within this limited demographic, clinical guidelines often prioritize hydrolyzed formulas over soy options due to the aforementioned safety concerns. This regulatory hierarchy caps market volume by categorizing the product as a niche medical intervention rather than a widely accessible nutritional alternative.

Key Market Trends

The integration of prebiotics and probiotics represents a critical evolution in the Global Soy Based Infant Formula Market, directly addressing historical concerns regarding the digestibility of plant proteins compared to human milk. Manufacturers are increasingly fortifying soy isolates with Human Milk Oligosaccharides (HMOs) and specific bacterial strains to optimize the infant microbiome and enhance nutrient absorption, effectively positioning these products as functional nutrition rather than merely allergen-avoidance tools. This focus on advanced formulation is bolstering the ingredient supply chain; according to DSM-Firmenich, February 2025, in the 'Full Year 2024 Results' report, the company achieved organic sales growth of 6%, driven significantly by improving demand for essential early life nutrition ingredients like HMOs within its Health, Nutrition & Care business unit.

Concurrently, there is a definitive strategic shift toward organic and non-GMO soy sourcing, driven by parental demand for transparency and the elimination of synthetic pesticides in infant diets. As soy is frequently associated with genetic modification, premium brands are rigorously adopting certified organic supply chains to mitigate health anxieties and differentiate their portfolios in a crowded marketplace. This trend is translating into tangible category expansion; according to the Organic Trade Association, April 2025, in the '2025 Organic Market Report', the organic baby food and formula category established itself as the second-largest organic grocery segment with sales reaching $1.6 billion in 2024, highlighting the commercial necessity for manufacturers to secure clean-label soy certifications.

Segmental Insights

The Online distribution channel is anticipated to witness the most rapid expansion within the Global Soy Based Infant Formula Market. This trajectory is primarily driven by the superior accessibility digital platforms offer for niche dietary products, which often face limited shelf space in physical retail outlets. Major e-commerce retailers facilitate consumer access to a diverse range of specialized formulas suitable for infants with galactosemia or lactose intolerance. Additionally, the convenience of subscription models and the ability to review detailed nutritional compliance information online significantly bolster consumer adoption of these digital procurement channels.

Regional Insights

Asia Pacific holds the dominant position in the global soy-based infant formula market, driven primarily by the high prevalence of lactose intolerance and cow milk protein allergies among the regional population. This physiological factor necessitates the widespread adoption of plant-based alternatives for infant nutrition. Furthermore, rapid urbanization in countries like China and India has increased the demand for convenient breast milk substitutes. Regulatory frameworks established by agencies such as the Food Safety and Standards Authority of India play a crucial role in standardizing these products, thereby enhancing parental trust and securing the region's market leadership.

Recent Developments

• In July 2024, the South Carolina Department of Public Health announced a new collaboration and contract transition for its WIC program, explicitly replacing the discontinued Gerber products with Abbott’s Similac brand. Effective from late July, the state’s authorized food list for infants requiring soy-based nutrition shifted from Gerber Good Start Soy to Similac Soy Isomil. This operational change ensured continued access to soy-based infant formula for participants and solidified the presence of the Similac soy product line within the state's public health nutrition network.
• In May 2024, the United States Department of Agriculture (USDA) issued a supply chain disruption declaration following the decision by Gerber to discontinue the production of its Gerber Good Start Soy powder infant formula. The notification informed State agencies administering the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) that the manufacturer would cease making this specific soy-based contract brand product. This discontinuation necessitated a market-wide adjustment, forcing state programs and parents to transition to alternative soy-based formula brands to meet the nutritional needs of infants requiring non-dairy options.
• In April 2024, Else Nutrition, a company specializing in plant-based alternatives to dairy and soy formulas, executed a significant expansion into the Asia-Pacific market with a product launch in Australia. The company introduced its range of non-dairy, non-soy infant and toddler nutrition products, formulated with almond, buckwheat, and tapioca, to Australian consumers. This strategic move was designed to capture the growing demand for plant-based infant nutrition in the region, positioning the brand as a direct competitor and alternative to traditional soy-based infant formulas in the established APAC market.
• In January 2024, the manufacturer of the Similac brand, including its Soy Isomil formulation, reported that it had successfully reclaimed its market-leading position in the United States infant formula market. Following a significant voluntary recall and production stoppage at its Sturgis, Michigan facility in 2022 which impacted the availability of various specialty and standard formulas, the company confirmed that its recovery efforts had restored its volume-based market share. This resurgence ensured the stabilized supply of its diverse nutritional portfolio, including its widely used soy-based options, to retailers and consumers across the country.

Key Market Players

• Danone S.A.
• HiPP GmbH & Co. Vertrieb KG
• Nestlé S.A.
• Abbott Laboratories
• The Kraft Heinz Company
• Reckitt Benckiser Group PLC
• Heilongjiang Feihe Dairy Co., Ltd.
• Arla Foods amba
• Kerry Group plc
• Royal FrieslandCampina N.V.

By Form	By Type	By Distribution Channel	By Region
Powder Liquid Semi-Liquid	Low Fat Soy-based Infant Formula Whole-Fat Soy-based Infant Formula	Online Offline	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Soy Based Infant Formula Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Soy Based Infant Formula Market, By Form:

• Powder
• Liquid
• Semi-Liquid

• Soy Based Infant Formula Market, By Type:

• Low Fat Soy-based Infant Formula
• Whole-Fat Soy-based Infant Formula

• Soy Based Infant Formula Market, By Distribution Channel:

• Online
• Offline

• Soy Based Infant Formula Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE